PT - JOURNAL ARTICLE AU - Holtgrewe, Lydia AU - Jain, Sonal AU - Dekova, Ralitza AU - Broger, Tobias AU - Isaacs, Chris AU - Nahid, Payam AU - Cattamanchi, Adithya AU - Denkinger, Claudia M. AU - Yerlikaya, Seda TI - Innovative COVID-19 Point-of-Care Diagnostics Suitable for Tuberculosis Diagnosis: A Scoping Review AID - 10.1101/2024.06.13.24308880 DP - 2024 Jan 01 TA - medRxiv PG - 2024.06.13.24308880 4099 - http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308880.short 4100 - http://medrxiv.org/content/early/2024/06/13/2024.06.13.24308880.full AB - Introduction Rapid and accurate point-of-care (POC) tuberculosis (TB) diagnostics are a key priority to close the TB diagnostic gap of 3.1 million people without a diagnosis. Leveraging the recent surge in COVID-19 diagnostic innovation, we explored the potential adaptation of commercially available SARS-CoV-2 tests for TB diagnosis, aligning with World Health Organization (WHO) target product profiles (TPPs).Methods A scoping review was conducted following PRISMA-ScR guidelines to systematically map commercially available POC molecular and antigen SARS-CoV-2 diagnostic tests potentially meeting the TPPs for TB diagnostic tests for peripheral settings. Data were gathered from PubMed/MEDLINE, bioRxiv, and medRxiv, along with publicly accessible in vitro diagnostic test databases, and developer websites, up to November 23, 2022. Data on developer and test attributes, operational characteristics, pricing, and clinical performance were charted using standardized data extraction forms. Each identified test was evaluated using a standardized scorecard. A narrative synthesis of the charted data is presented.Results Our database search yielded 2,003 studies, from which 408 were considered eligible. Among these, we identified 58 commercialized diagnostic devices, including 17 near-POC antigen tests, one POC molecular test, 29 near-POC molecular tests, and 11 low-complexity molecular tests. We summarized the detailed characteristics, regulatory status, and clinical performance data of these tests. The LumiraDx (Roche, Switzerland) emerged as the highest- scoring near-POC antigen platform, while Visby (Visby, USA) was the highest-performing near-POC molecular platform. The Lucira Check-It (Pfizer, USA) was noted as the sole POC molecular test. The IdyllaTM (Biocartis, Switzerland) was identified as the leading low- complexity molecular test.Discussion We highlight a diverse landscape of commercially available diagnostic tests suitable for potential adaptation to TB POC testing. This work aims to bolster global TB initiatives by fostering stakeholder collaboration, leveraging COVID-19 diagnostic technologies for TB diagnosis, and uncovering new commercial avenues to tackle longstanding challenges in TB diagnosis.Competing Interest StatementAuthors declare no financial conflict of interest. T.B. holds patents in the fields of lipoarabinomannan detection and aerosol collection, and is a shareholder of Avelo Ltd, a Swiss diagnostics company. C.I. is the founder and director of Connected Diagnostics Limited, a UK-based commercial entity that assists companies with the development of diagnostic devices. C.D. is a member of the Scientific Advisory Committee of Avelo Ltd.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/36754560/ Funding StatementThis systematic review is funded by the National Institutes of Health (NIH) (funding reference number U01AI152087; Rapid Research in Diagnostics Development for Tuberculosis Network).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors